Prognostic value of circulating tumor cells in advanced gastric cancer patients receiving chemotherapy

Liu, Yongping; Ling, Yang; Qi, Qiufeng; Feng, Li; Zhu, Ming; Zhang, Yaping; Bao, Yanqing; Zhang, Changsong

doi:10.3892/mco.2017.1125

Cited by 30 publications

(18 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, CTCs have emerged as an important tumor biomarker for a wide range of human cancers . Our previous reports of CTC analyses in advanced NSCLC mainly focusing on patients without oncogenic mutations receiving chemotherapy as first‐line treatment demonstrated that CTC counts at baseline and during follow‐up are a strong independent predictor of survival outcomes .…”

Section: Discussionmentioning

confidence: 99%

Prognostic role of circulating tumor cells in patients with EGFR‐mutated or ALK‐rearranged non‐small cell lung cancer

Tong

Zhao

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundCirculating tumor cell (CTC) counts at baseline and follow‐up are an independent prognostic factor in patients receiving standard chemotherapy for non‐small cell lung cancer (NSCLC). This study further explored the role of CTCs in EGFR‐mutated and ALK‐rearranged NSCLC patients administered targeted therapies as first‐line treatment.MethodsCTCs were enumerated with a novel high‐efficiency detection method from the blood of 43 patients with EGFR‐mutated or ALK‐rearranged NSCLC at baseline and at disease‐progression. Patients were stratified into favorable and unfavorable groups with baseline CTC counts of < 8 or ≥ 8 CTCs/3.2 mL, respectively.ResultsA total of 76.7% of the patients were positive for ≥ 2 CTCs /3.2 ml blood at baseline. The median progression‐free survival (PFS) and overall survival (OS) rates of the favorable compared to the unfavorable group were longer (11.6 vs. 8.5 months, P = 0.004 for PFS; 21.00 vs. 17.7 months, P = 0.013 for OS). Multivariate analysis demonstrated that baseline CTC count was a strong predictor of PFS (hazard ratio 2.835; 95% confidence interval 1.240–6.483; P = 0.014) and OS (hazard ratio 3.317; 95% confidence interval 1.360–8.092; P = 0.008).ConclusionBaseline CTC count could be a predictive biomarker for EGFR‐mutated and ALK‐rearranged NSCLCs, which allows for better guidance and monitoring of patients over the course of molecular targeted therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic role of circulating tumor cells in patients with EGFR‐mutated or ALK‐rearranged non‐small cell lung cancer

Tong

Zhao

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…In contrast, a continuously favorable CTC count or an early shift into a favorable CTC count following therapy could predict an improved prognosis. Similarly, in Liu's report [59], only those patients with a low baseline CTC level or a decreased CTC level after the first cycle of chemotherapy remarkably benefited from the treatment. Those with a baseline CTC level of > 2 cells/5 mL blood, which was determined as an independent poor prognostic marker for PFS and OS, were spared from the adverse reactions of chemotherapy.…”

Section: Ctc Assay For Prognosis and Treatment Management Of Gcmentioning

confidence: 74%

“…[55] The baseline CTC count of >2 cells/5 mL and an increase of the CTC count after the first cycle of chemotherapy was an independent prognostic marker of poor PFS and OS→ patients with a low baseline CTC count or decrease of the CTC count after the first cycle of chemotherapy may benefit significantly from palliative chemotherapy [59] The threshold number of CTCs is significantly associated with different clinical stages and was positively correlated with the value in U/mL of CA724. CTCs technology based on ISET method has a high detection rate.…”

Section: Clinical Implication Of Ctcs In Gcmentioning

confidence: 99%

Emerging Role of Circulating Tumor Cells in Gastric Cancer

Huong

Gurshaney

Bình

et al. 2020

Cancers

View full text Add to dashboard Cite

With over 1 million incidence cases and more than 780,000 deaths in 2018, gastric cancer (GC) was ranked as the 5th most common cancer and the 3rd leading cause of cancer deaths worldwide. Though several biomarkers, including carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), and cancer antigen 72-4 (CA72-4), have been identified, their diagnostic accuracies were modest. Circulating tumor cells (CTCs), cells derived from tumors and present in body fluids, have recently emerged as promising biomarkers, diagnostically and prognostically, of cancers, including GC. In this review, we present the landscape of CTCs from migration, to the presence in circulation, biologic properties, and morphologic heterogeneities. We evaluated clinical implications of CTCs in GC patients, including diagnosis, prognosis, and therapeutic management, as well as their application in immunotherapy. On the one hand, major challenges in using CTCs in GC were analyzed, from the differences of cut-off values of CTC positivity, to techniques used for sampling, storage conditions, and CTC molecular markers, as well as the unavailability of relevant enrichment and detection techniques. On the other hand, we discussed future perspectives of using CTCs in GC management and research, including the use of circulating tumor microembolies; of CTC checkpoint blockade in immunotherapy; and of organoid models. Despite the fact that there are remaining challenges in techniques, CTCs have potential as novel biomarkers and/or a non-invasive method for diagnostics, prognostics, and treatment monitoring of GC, particularly in the era of precision medicine.

show abstract

“…Eighteen of the remaining 21 articles [16, 20, 21, 23, 24, 26, 29, 30, 32-34, 38, 40, 42, 48, 50-52] with 21 arms provided HRs for OS. Nine articles [12,16,20,21,23,24,29,30,40] with 11 arms provided HRs for PFS, and 3 articles [37,39,52] provided HRs for DFS.…”

Section: Study Characteristicsmentioning

confidence: 99%

Circulating Tumour Cells (CTCs) as Potential Biomarkers of Clinicopathological and Prognostic Significance in Gastric Cancer Patients: A Systematic Review and Meta-Analysis

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Gastric cancer (GC) is a common highly recurrent malignant tumor that is associated with poor prognosis. Circulating tumor cells (CTCs) have drawn much attention because of their diagnostic value in diverse cancers, including GC. This study aimed to assess the relevance of CTCs in predicting the clinicopathological parameters and prognostic significance of GC. Methods: We systematically searched PubMed, Medline and Web of Science for relevant studies. Each database was searched from its date of inception through January 22, 2020. The odds ratios (ORs), hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated as effect values using the random-effects model. Results: In total, 52 articles that reported 68 studies comprising 4158 GC patients were included. The pooled results on TNM stage indicated that the III/IV group had a notably higher CTCs positivity rate than the I/II group (OR=2.73, 95% CI (1.95,3.82), I2=65%). The poorly differentiated group had a significantly higher CTCs positivity rate than the well/moderately differentiated group (overall: OR=1.91, 95% CI (0.77,4.71)), as well as the Lauren classification diffuse/hybrid type group and the intestinal group (overall: OR=1.77, 95% CI (0.70,4.44)). The bulk of analysis revealed that CTC positivity detected in GC patients was correlated with worse overall survival (OS) (HR =1.94, 95% CI (1.64,2.30), P≤0.001), progression-free survival (PFS) (HR =2.45, 95% CI (1.65,3.64), P≤0.001), and disease-free survival (DFS) (HR =2.78, 95% CI (1.89,4.10), P≤0.001). Then, we extracted data and analyzed the DCR of chemotherapy in patients with GC, and the pooled analysis demonstrated that the DCR of the CTC positivity was lower than that of the CTC negativity (RR =0.63, 95% CI (0.44,0.91))Conclusions: In conclusion, our study demonstrated that the CTCs positivity was correlated with the poor OS, PFS and DFS in GC patients and provided a scientific foundation for gastric cancer staging.

show abstract

Prognostic value of circulating tumor cells in advanced gastric cancer patients receiving chemotherapy

Cited by 30 publications

References 33 publications

Prognostic role of circulating tumor cells in patients with EGFR‐mutated or ALK‐rearranged non‐small cell lung cancer

Prognostic role of circulating tumor cells in patients with EGFR‐mutated or ALK‐rearranged non‐small cell lung cancer

Emerging Role of Circulating Tumor Cells in Gastric Cancer

Circulating Tumour Cells (CTCs) as Potential Biomarkers of Clinicopathological and Prognostic Significance in Gastric Cancer Patients: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About